Maf expression in human macrophages and lymph node sinus macrophages in patients with esophageal cancer

Hiroto Takeya, Koji Ohnishi, Takuya Shiota, Yoichi Saito, Yukio Fujiwara, Taisuke Yagi, Yuki Kiyozumi, Yoshifumi Baba, Naoya Yoshida, Kenichi Asano, Masato Tanaka, Hideo Baba, Yoshihiro Komohara

The large Maf transcription factors are expressed in immune cells including macrophages and lymphocytes. To investigate the distribution of Maf expression in human organs, immunostaining for Maf was performed using sections of several human organs. High Maf expression was seen in the nucleus of macrophages in the gastrointestinal tract and lymph node sinus macrophages (LySMs). Then, we assessed whether Maf expression in LySMs was correlated with CD169 expression and the clinical prognosis in patients with esophageal cancer. Maf expression was associated with CD169 expression, but Maf expression in LySMs was not associated with the clinical course in patients with esophageal cancer. We determined which cytokines stimulate Maf expression using cultured macrophages. Immunocytochemistry showed that Maf expression was significantly elevated by interferon-γ. These results are the first report of Maf expression in human samples. Maf expression may be a marker for the macrophage population in humans.

Keywords: Maf, macrophage, CD169, esophageal cancer, LySM

INTRODUCTION

Maf (also called c-Maf or MAF transcription factor) is a large Maf transcription factor that binds to the Maf recognition element. Maf is expressed in immune cells including macrophages and lymphocytes. Maf expression is linked to Th2 differentiation in lymphocytes, and the observation that Maf is closely involved in F4/80 expression in macrophages suggests a significant role for Maf in macrophage differentiation. Maf deficiency induces down-regulation of vascular cell adhesion molecule 1 in fetal liver macrophages and abrogates erythropoiesis in fetal liver. Maf may also be involved in CCL8 production from sialoadhesin (Siglec-1, CD169)-positive macrophages in mice.

Thus, many studies have investigated Maf, but only a few studies have examined Maf expression in human samples. Following a report of Maf overexpression in angioimmunoblastic T-cell lymphoma, overexpression of Maf protein was shown in myeloma, T-cell lymphoma, and natural killer/T-cell lymphoma. In a study using a murine model, Maf overexpression in T lymphocytes induced the development of T-cell lymphoma, suggesting that Maf protein leads to malignant transformation in T lymphocytes. In normal tissues, Maf expression is detected in the subpopulation of plasma cells, lymphocytes, and macrophages in hematopoietic organs, although the expression levels are weak. However, Maf expression was examined only in hematopoietic and lymphoid organs. In the present study, we investigated Maf expression in human organs and showed that Maf expression was present in resident macrophages in the gastrointestinal tract and lymph nodes. Maf expression was expressed in lymph node sinus macrophages (LySMs), which are antigen-presenting cells that contribute to anti-viral and anti-cancer immune responses. We previously reported that increased CD169 expression in LySMs was correlated with increased infiltration of lymphocytes into cancer tissues and a better clinical course in several malignant cancers including esophageal cancer. Therefore, here we tested if Maf expression in LySMs was correlated with CD169 expression and the clinical prognosis in patients with esophageal cancer.
using the same lymph node samples.

MATERIALS AND METHODS

Samples

Paraffin-embedded samples of several organs other than gastro-intestinal tracts were prepared from specimens obtained from three autopsy cases at Kumamoto University Hospital. Samples of stomach and small/large intestine were obtained from the non-cancerous part of resected colon cancer samples. Paraffin-embedded lymph node samples were prepared from specimens obtained from 182 patients diagnosed with esophageal cancer between 2005 and 2013 at Kumamoto University Hospital. Written informed consent was obtained from all patients in accordance with protocols of the Kumamoto University Review Board, and the study design was approved by the Kumamoto University Review Board (#1174, #2224). Cancer staging was performed according to the American Joint Committee on Cancer Staging Manual (7th edition). In cases involving lymph node metastasis, only cancer cell-free lymph nodes were used for the analysis.

Immunohistochemistry

Single and double immunohistochemical staining was performed as described previously. In brief, deparaffinized sections were microwave treated in 1 mM EDTA (pH 8.0). Then, sections were incubated with anti-Maf antibody (clone EPR16484, Abcam), anti-CD204 (scavenger receptor A type I and II or macrophage scavenger receptor 1) antibody (clone SRA-E5, Cosmo Bio, Tokyo, Japan), or anti-CD169 antibody (clone HSn 7D2; Santa Cruz Biotechnology, CA, USA). Horseradish peroxidase-labeled anti-mouse or anti-rabbit immunoglobulin antibody (Nichirei, Tokyo, Japan) was used as the secondary antibody. Diaminobenzidine (brown color) and HistoGreen (green color) substrate (#AYS-E109, Cosmo Bio) were used for visualization of positive signals. The specificity of anti-Maf antibody was checked by immunohistochemistry using cell block specimens of RPMI8226 (Maf-positive, gifted from Dr. Yutaka Okuno, Kumamoto University) and MOLT4 (Maf-negative, purchased from JCB cell bank, Osaka, Japan). Scoring of Maf was done according to our previously published study. The immunohistochemical data for CD169 in patients with esophageal cancer were previously published. For scoring of Maf expression, all samples were evaluated microscopically by two pathologists (H. T. and K. O.) who were blinded to the patient’s information. The intensity score and the proportion score were determined based on the intensity (score 0; negative, 1; weak, 2; moderate, or 3; strong) or the proportion score were determined based on the intensity (score 0; negative, 1; 1%-10%, 2; 11%-50%, or 3; >50%), respectively. The Maf score was calculated by adding the intensity (0-3) and the proportion (0-3) scores and ranged from 0 to 6. The average of the total score of the two pathologists was the final score.

RESULTS

Macrophages in intestines and lymph nodes express Maf protein.

Peripheral blood mononuclear cells were obtained from healthy volunteer donors who each provided written informed consent for the use of their cells in accordance with the study protocols approved by the Kumamoto University Hospital Review Board (#1169). Monocytes were isolated using RosettSep cocktail (StemCell Tech., Vancouver, Canada), plated in UpCELL culture plates (CellSeed, Tokyo, Japan), and cultured in 2% human serum, 1 ng/mL granulocyte macrophage-colony stimulating factor (WAKO, Tokyo, Japan), and 50 ng/mL macrophage-colony stimulating factor (WAKO) for 7 days to induce macrophage differentiation. Macrophages (2 × 10⁵/well) were then seeded on glass coverslips in a 12-well plate and stimulated with interleukin (IL)-10 (#093-04651, 10 ng/mL, WAKO), interferon (IFN)-α (#11200-2, 10 ng/mL, R&D Systems, Minneapolis, MN, USA), IFN-γ (#IFG4001, 10 ng/mL, WAKO), or lipopolysaccharide (LPS) (#L2654, 100 ng/mL, Sigma, St. Louis, MO, USA) for 1 day. Cells were fixed with 1% paraformaldehyde and then dried once. Cells were blocked with 1% bovine serum albumin and then stained with anti-Maf antibody. Horseradish peroxidase-labeled anti-rabbit immunoglobulin antibody (Nichirei) was used as the secondary antibody, and dianimobenzidine substrate was used for visualization.

Statistics

JMP10 software (SAS Institute, Chicago, IL, USA) was used for statistical analyses. The cumulative survival rate was compared between two groups using the log-rank test and Wilcoxon test. The median was used as the cut-off value for comparisons between two groups. The Chi square test and Student’s t-test were also performed. A p-value of <0.05 was considered to indicate a statistically significant difference.
Maf expression in human tissues

Fig. 1. Immunohistochemistry for Maf. (A) Single immunostaining for Maf was performed on sections of cell blocks of two cell lines (RPMI8226 and MOLT4). Scale bar; 20 μm. (B) Single immunostaining for Maf and CD204 (a marker for macrophages) and double immunostaining for Maf (green) and CD204 (brown) were performed on sections of lymph nodes and colon. Scale bar; 100 μm.

Table 1. c-Maf expression in different human organs

| Tissues                  | c-Maf          | Tissues                  | c-Maf          |
|--------------------------|----------------|--------------------------|----------------|
| Heart                    | Intermuscular Mφ ± | Thyroid                  | Mφ in lamina propria - |
| Lung                     | Alveolar Mφ -     | Trachea                  | Intestinal Mφ - |
| Liver                    | Kupffer cells -   | Esophagus                | -              |
|                          | Mφ in portal triads - | Stomach              | -              |
| Kidney                   | Interstitial Mφ - | Adrenal                  | Mφ in lamina propria + |
|                          | Uriniferous tubule cells - | -            | -              |
| Spleen                   | Red pulp Mφ -    | Prostate                 | Intestinal Mφ - |
|                          | White pulp Mφ -  | Aorta                    | -              |
| Thymus                   | Mφ in cortex -   | Large intestine          | Mφ in lamina propria + |
|                          | Mφ in medulla -  | Small intestine          | -              |
| Lymph nodes              | Mφ in follicles + | Cerebrum                 | Mφ in lamina propria + |
|                          | Mφ in paracortical areas + | Cerebellum | -              |
| Pancreas                 | Intestinal Mφ -  | Bone marrow              | ±              |

+; positive, ±; weakly positive, -; negative, Mφ; macrophage.
Maf expression in LySMs in patients with esophageal cancer.

We previously showed that CD169 expression in LySMs of non-metastatic regional lymph nodes was correlated with better clinical prognosis in patients with esophageal cancer. In the present study, we examined the expression of Maf in the same samples used in the previous study. The distribution of the final scores is shown in Figure 2A and Table 2. Cases with a score >4 were classified as “high” to divide the distribution of final scores. Double immunostaining for CD169 and Maf showed that a portion of Maf-positive LySMs were also positive for CD169 (Figure 2C). Statistical analysis demonstrated that the high-Maf cases were preferentially associated with high-CD169 cases (Figure 2D). However, Maf expression in LySMs was not associated with any clinicopathological factors and the clinical course in patients with esophageal cancer (Figure 2E, Table 2).

Increased expression of Maf protein was seen in IFN-γ-stimulated macrophages.

Next we tested which cytokines stimulate Maf expression in cultured macrophages. Monocytes derived from peripheral blood were differentiated into macrophages and then stimulated with IFN-α, IFN-γ, IL-10, or LPS. Immunocytochemistry showed that Maf expression was significantly elevated by IFN-γ (Figure 3), whereas no significant effect was observed on macrophages treated with IFN-α, IL-10, or LPS.

DISCUSSION

In the present study, we performed double immunostaining for Maf and CD204 (a marker for macrophages), and strong Maf expression was seen in resident macrophages in the human stomach, small/large intestine, and lymph nodes, consistent with previous studies in mice. In addition, although Maf plays a critical role in Th differentiation in lymphocytes, no positive signals were seen in lymphocytes in human organs. The sensitivity of immunohistochemistry...
Table 2. Relationship between expression of Maf and clinicopathological feature

|                          | n= 182 | c-Maf expression |       |
|--------------------------|--------|------------------|-------|
|                          |        | Low              | High  |
| Mean age (years)         |        | 66.94            | 65.25 | N.S.  |
| Gender                   |        |                  |       |
| Male                     | 160    | 97               | 53    | N.S.  |
| Female                   | 22     | 18               | 4     |
| Histology                |        |                  |       |
| SCC                      | 166    | 102              | 64    | N.S.  |
| others                   | 16     | 13               | 3     |
| T status                 |        |                  |       |
| pT1                      | 92     | 59               | 33    | N.S.  |
| pT2                      | 23     | 13               | 10    |
| pT3                      | 61     | 37               | 24    |
| pT4                      | 6      | 6                | 0     |
| Pretreatment             |        |                  |       |
| Chemotherapy             | 74     | 46               | 28    | N.S.  |
| None                     | 108    | 69               | 39    |
| Stage                    |        |                  |       |
| I                        | 69     | 43               | 26    | N.S.  |
| II                       | 63     | 41               | 22    |
| III                      | 41     | 27               | 14    |
| IV                       | 9      | 4                | 5     |
| LV invasion              |        |                  |       |
| Negative                 | 95     | 60               | 35    | N.S.  |
| Positive                 | 87     | 55               | 32    |

SCC: squamous cell carcinoma, LV: lymphovascular. N.S.; statistically not significant.

Fig. 3. Immunocytochemistry for Maf. Immunostaining for Maf was performed using cultured macrophages treated with IFN-α, IFN-γ, IL-10, or LPS. Positive signals were seen in the nucleus, and the percent positive cells was calculated (n = 3 per sample).
is generally weaker than that of flow cytometry or PCR, and these technical factors may be the reasons for this discrepancy. Furthermore, the signal intensity of Maf was weaker in autopsy specimens than surgically resected samples including gastro-intestinal tracts and lymph nodes in the present study. The possibility that the discrepancy of fixation period and postmortem alterations between autopsy samples and surgically resected materials influenced the Maf-positive signals cannot be excluded.

Another interesting observation of this study is that a portion of Maf-positive LySMs was negative for CD169, suggesting a complex heterogeneity for LySMs. We previously demonstrated that CD169 expression in human monocyte-derived macrophages was elevated by IFN-α, IFN-β, IFN-γ, and LPS, and the most significant up-regulation was induced by IFN-α and IFN-β. In the present study, Maf expression was significantly induced by IFN-γ but not by IFN-α or LPS. We also previously showed that expression of indoleamine 2,3-dioxygenase in human monocyte-derived macrophages was elevated by IFN-α, IFN-β, IFN-γ, and LPS, with the most significant up-regulation induced by IFN-γ. Indoleamine 2,3-dioxygenase expression does not overlap with CD169 expression in LySMs, and thus, we suggest that at least two subpopulations of LySMs exist. Resident and exudate macrophages may co-exist in lymph nodes and other organs. In addition, some resident macrophages are considered to originate from yolk sac primitive macrophages, which have self-renewal ability. Fate mapping studies have revealed the heterogeneity of resident macrophages in several organs, although few studies have investigated the heterogeneity of macrophages in lymph nodes. Further studies are necessary to reveal the heterogeneity of macrophages in lymph nodes.

In conclusion, Maf expression was detected in resident macrophages in the gastrointestinal tract and lymph nodes with immunohistochemistry. In patients with esophageal cancer, Maf expression was positively associated with CD169 expression. Maf expression was induced by IFN-γ stimulation of cultured macrophages. These results are the first report of Maf expression in human samples. Maf expression may be a marker for the macrophage subpopulation in humans.

ACKNOWLEDGMENTS

We thank Ms. Ikuko Miyakawa and Mr. Takenobu Nakagawa for their technical assistance. We also appreciate Dr. Daiki Yoshii for statistical support. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 16H05162, 16K15248, 17H04060).

CONFLICT OF INTEREST

All authors have no financial competing interests to declare.

REFERENCES

1. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell. 1996; 85 : 973-983.
2. Li-Weber M, Salgame P, Hu C, et al. Th2-specific protein/DNA interactions at the proximal nuclear factor-AT site contribute to the functional activity of the human IL-4 promoter. J Immunol. 1998; 161 : 1380-1389.
3. Daassi D, Hamada M, Jeon H, et al. Differential expression patterns of MafB and c-Maf in macrophages in vivo and in vitro. Biochem Biophys Res Commun. 2016; 473 : 118-124.
4. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med. 1998; 188 : 1859-1866.
5. Li B, Tournier C, Davis RJ, Flavell RA. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J. 1999; 18 : 420-432.
6. Nakamura M, Hamada M, Hasegawa K, et al. c-Maf is essential for the F4/80 expression in macrophages in vivo. Gene. 2009; 445 : 66-72.
7. Kusakabe M, Hasegawa K, Hamada M, et al. c-Maf plays a crucial role for the definitive erythropoiesis that accompanies erythroblastic island formation in the fetal liver. Blood. 2011; 118 : 1374-1385.
8. Kikuchi K, Iida M, Ikeda N, et al. Macrophages Switch Their Phenotype by Regulating Maf Expression during Different Phases of Inflammation. J Immunol. 2018; 201 : 635-651.
9. Murakami YI, Yatabe Y, Sakaguchi T, et al. c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2007; 31 : 1695-1702.
10. Natkunam Y, Tedoldi S, Paterson JC, et al. Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia. Am J Clin Pathol. 2009; 132 : 361-371.
11. Morito N, Yoh K, Fujioka Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res. 2006; 66 : 812-819.
12. Teijaro JR. Too much of a good thing: Sustained type 1 interferon signaling limits humoral responses to secondary viral infection. Eur J Immunol. 2016; 46 : 300-302.
13. Asano K, Kikuchi K, Tanaka M. CD169 macrophages regulate immune responses toward particulate materials in the circulating fluid. J Biochem. 2018; 164 : 77-85.
14. Asano K, Nabeyama A, Miyake Y, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011; 34 : 85-95.
15. Komohara Y, Ohnishi K, Takeya M. Possible functions of CD169-positive sinus macrophages in lymph nodes in antitumor immune responses. Cancer Sci. 2017; 108 : 290-295.
16. Takeya H, Shiota T, Yagi T, et al. High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer. Pathol Int. 2018; 68 : 685-693.
17. Nakagawa T, Ohnishi K, Kosaki Y, et al. Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J...
Clin Exp Hematop. 2017; 57 : 31-36.
18 Asano T, Ohnishi K, Shiota T, et al. CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. Cancer Sci. 2018; 109 : 1723-1730.
19 Sato K, Miyoshi F, Yokota K, et al. Marked induction of c-Maf protein during Th17 cell differentiation and its implication in memory Th cell development. J Biol Chem. 2011; 286 : 14963-14971.
20 Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol. 2009; 10 : 167-175.
21 Ohnishi K, Komohara Y, Saito Y, et al. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci. 2013; 104 : 1237-1244.
22 Miyasato Y, Takashima Y, Takeya H, et al. The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma. J Clin Exp Hematop. 2018; 58 : 95-101.
23 Kuka M, Iannacone M. The role of lymph node sinus macrophages in host defense. Ann N Y Acad Sci. 2014; 1319 : 38-46.
24 Perdiguerio EG, Geissmann F. The development and maintenance of resident macrophages. Nat Immunol. 2016; 17 : 2-8.
25 Hoeffel G, Ginhoux F. Ontogeny of Tissue-Resident Macrophages. Front Immunol. 2015; 6 : 486.